CN1823795A - Medicinal composition for treating diabetes and its preparation method - Google Patents
Medicinal composition for treating diabetes and its preparation method Download PDFInfo
- Publication number
- CN1823795A CN1823795A CN 200510135551 CN200510135551A CN1823795A CN 1823795 A CN1823795 A CN 1823795A CN 200510135551 CN200510135551 CN 200510135551 CN 200510135551 A CN200510135551 A CN 200510135551A CN 1823795 A CN1823795 A CN 1823795A
- Authority
- CN
- China
- Prior art keywords
- acarbose
- dimethicone
- composition
- weight
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A composite medicine for treating diabetes contains acarbase, dimethyl silicon oil, absorbent and medicinal auxiliary. Its preparing process is also disclosed.
Description
Invention field
The present invention relates to medical technical field, exactly the present invention relates to a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof.
Background of invention
China's diabetes number has reached 2,380 ten thousand, is the maximum country of onset diabetes number.Diabetic brings white elephant to society.
Diabetes have great harm to health, and this harm takes place unconsciously often, if a patient do not note at ordinary times, in case the acute complications of diabetes has taken place, can jeopardize patient's life sometimes.The chronic complicating diseases of diabetes is because the blood glucose long-term control is bad, accumulates over a long period and a kind of change of causing, comprises trunk, blood capillary and neuropathy, health of people level and work capacity is descended greatly, even cause maimed person or premature dead.
At present the medicine of treatment diabetes mainly contains insulin, sulphanylureas and biguanides, alpha-glucosidase inhibitor, regulator, euglycemic agent etc. before the meal.With producing antibody, biological activity reduces insulin for a long time, and dosage increases, and produces hyperinsulinemia, impels microangiopathies to take place; Sulphanylureas passes through the stimulating pancreas excreting insulin and blood sugar lowering; Biguanides is then by increasing peripheral tissues to the utilization of glucose and blood sugar lowering.Sulphanylureas and biguanides all have curative effect preferably to the fasting glucose that reduces the type ii diabetes patient, but very limited to the effect that reduces post-prandial glycemia.Post-prandial glycemia is the blood sugar level acme in the diabetics one day, and its persistent period can be for 8 hours, and long-time high-caliber post-prandial glycemia can increase the weight of diabetes and cause complications.Therefore, the control post-prandial glycemia is the important measures that prevent and treat diabetes and complication thereof.
Acarbose is as the alpha-glucosidase inhibitor of the brand-new mechanism of action of a class, be first oral drugs that mainly postprandial hyperglycemia played therapeutical effect, it has high-affinity and can be competitive to the pancreatic amylase in the small intestinal and alpha-glucosaccharase hydrolytic enzyme, can reversibly suppress amylase and alpha-glucosaccharase hydrolytic enzyme, thereby disaccharidase in the interference food, the hydrolysis of polysaccharide, its absorption on duodenum and jejunum top is tailed off, thereby being deferred to the small intestinal middle and lower part slowly absorbs, finally delay and reduced the absorption of glucose and other monosaccharide, effectively postpone and alleviate the time and the degree of post-prandial glycemia rising, take for a long time also and can reduce fasting blood glucose level, this type of medicine is to I, type ii diabetes all is suitable for.Acarbose can be used for the diabetes of insulin-dependent or non-insulin-depending type as the new oral blood sugar lowering, also can use with other oral hypoglycemics or insulin combination.
At present, the acarbose preparation variety that has gone on the market has two kinds of ordinary tablet and capsules, clinical experiment shows, acarbose can reduce patient's blood glucose value after the meal significantly, but modal untoward reaction is a gastrointestinal reaction, mainly be to cause the many gas of intestinal, abdominal distention, stomachache etc., have many patients to end treatment because of gastrointestinal reaction.In addition, constipation also is to increase the weight of the unsettled assignable cause of diabetics blood glucose, constipation makes disaccharidase in carbohydrate that patient takes in, the food, polysaccharide longer in the time that human body stops, and it is more to change into sugar, has influenced the hypoglycemic effect of acarbose greatly.
Therefore, the medical worker of this area still studies and inquires into better acarbose preparation variety constantly, to satisfy the demand of diabetics clinical application.
Summary of the invention
The objective of the invention is to overcome the defective that existing acarbose preparation exists, thereby specific adjuvant and proportioning provide that a kind of therapeutic effect is good by adopting, the Acarbose medicine composition that is used for the treatment of diabetes of stable curative effect and few side effects, good moldability, specifically, the side effect of a kind of reduction gastrointestinal reaction is provided, remove the acarbose preparation of diabetics constipation misery, thereby improve the compliance of patient.
One object of the present invention just provides a kind of Acarbose medicine composition for the treatment of diabetes.
Another object of the present invention provides a kind of method for preparing the Acarbose medicine composition of described treatment diabetes.
The objective of the invention is to realize by the following technical solutions:
A kind of Acarbose medicine composition for the treatment of diabetes, by the weight of this pharmaceutical composition, it comprises
Acarbose 1-50%,
Dimethicone 1-50%,
Absorbent 5-80%,
Pharmaceutic adjuvant acceptable 10-90%, wherein the weight ratio of acarbose and dimethicone is 1: 10-20: 1.
Preferably, the Acarbose medicine composition of treatment diabetes of the present invention, by the weight of this pharmaceutical composition, it comprises:
Acarbose 5-50%,
Dimethicone 5-50%,
Absorbent 5-70%,
Pharmaceutic adjuvant acceptable 20-80%,
Wherein the weight ratio of acarbose and dimethicone is 1: 5-15: 1.
It is a kind of composite oligosaccharide that is produced by actinomycete fermentation that the present invention treats the acarbose that adopts in the pharmaceutical composition of diabetes, only act on digestive tract, it carries out metabolism at digestive tract, mainly decomposed by intestinal bacteria, part is by the digestive enzyme hydrolysis, and the part of metabolite is passed through homaluria after absorbing.Acarbose is treated content in the pharmaceutical composition of diabetes in the present invention, counts 1-50% by the weight of said composition, is preferably 5-50%, more preferably 5-30%.
The molecular formula that the present invention treats the dimethicone that adopts in the pharmaceutical composition of diabetes for (SiO (CH3) 2] nSi (CH2) 4.The degree of polymerization of the dimethicone that the present invention adopts is 20-400, and kinematic viscosity is 20-1000mm
2/ s, it has good flowability.Dimethicone role in pharmaceutical composition of the present invention is the foam of eliminating in the gastrointestinal tract, the gas that is stored by foam is got rid of, thereby flatulence is alleviated, elimination or the many gas of reduction intestinal, abdominal distention, alleviate the side effect of acarbose, thereby improve patient's treatment compliance, reach the purpose of adhering to long-term treatment.In addition because the dimethicone surface tension is little, can reduce the surface tension of stool, can lubricate intestinal wall, make moisture immerse stool, make it to expand, can soften stool, make and be convenient to discharge, thereby the patient who makes diabetes merge constipation removes misery, reduce the time that carbohydrate and saccharide stop in vivo, reduce the conversion of sugar, thereby assist the acarbose blood sugar lowering.Dimethicone is treated content in the pharmaceutical composition of diabetes in the present invention, counts 1-50% by the weight of said composition, is preferably 5-50%, more preferably 5-20%.
The present invention treats and adopts the acarbose and the dimethicone of constant weight ratio to eliminate the side effect that acarbose causes in the pharmaceutical composition of diabetes, generally, the weight ratio of acarbose and dimethicone is 1: 10-20: 1, preferred 1: 5-15: 1, more preferably 1: 4-10: 1.
The absorbent that adopts in the pharmaceutical composition is one or more any mixture in starch, magnesium oxide, light magnesium oxide, silica gel, micropowder silica gel, magnesium carbonate, the basic magnesium carbonate, is preferably micropowder silica gel.The absorbent that adopts among the present invention is to be used to absorb dimethicone, to be prepared into various solid preparations with other pharmaceutic adjuvants again after the dimethicone absorption, so that solid drugs good moldability of the present invention, the absorbent that the present invention simultaneously adopts can not produce the side effect of constipation even can produce the effect of relieving constipation.The content of absorbent in pharmaceutical composition of the present invention is counted 5-80% by the weight of said composition, is preferably 5-70%, more preferably 10-50%.
Pharmaceutic adjuvant acceptable comprises one or more any mixture in diluent, disintegrating agent, binding agent, lubricant, fluidizer and the solvent in the pharmaceutical composition of the present invention, the content of pharmaceutic adjuvant acceptable in pharmaceutical composition of the present invention, weight by said composition is generally 10-90%, be preferably 20-80%, more preferably 20-60%.
Diluent can be any conventional diluent of this area, one or more any mixture that comprises starch and derivant thereof, dextrin, cellulose and derivatives class thereof, inorganic salts, its content in pharmaceutical composition of the present invention, weight by said composition is generally 20-80%, is preferably 30-60%.
Disintegrating agent can be any conventional disintegrating agent of this area, comprise dried starch, pregelatinized Starch, little smart cellulose, alginic acid and salt thereof, carboxymethyl starch sodium, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, methylcellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, the any mixture of one or more in the carboxymethylcellulose calcium, its content in pharmaceutical composition of the present invention, weight by said composition is generally 0.5-20%, is preferably 1-8%.
Binding agent can be any conventional binding agent of this area, comprise one or more any mixture in polyvinylpyrrolidone, starch, pregelatinized Starch, gelatin, arabic gum, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, the hydroxypropyl methyl fiber etc., its content in pharmaceutical composition of the present invention, weight by this pharmaceutical composition is generally 0.1-60%, preferred 0.2-20%.If other selected adjuvant character are fit to, can add binding agent.
Lubricant can be any traditional lubrication agent of this area, comprise magnesium stearate, calcium stearate, Glyceryl Behenate, the any mixture of one or more in glyceryl monostearate, stearic acid, hydrogenated vegetable oil, month pure magnesium sulfate of extension, polyethylene glycols, the Pulvis Talci, its content in pharmaceutical composition of the present invention, weight by said composition is generally 0.1-5%, is preferably 0.5-2%.
Fluidizer can be any conventional fluidizer of this area, comprise Pulvis Talci, Powderd cellulose, magnesium silicate, the mixture of one or more in magnesium trisilicate, the magnesium stearate, its content in pharmaceutical composition of the present invention, weight by said composition is generally 0.1-5%, is preferably 0.5-2%.
Employed solvent comprises water or ethanol in the pharmaceutical composition of the present invention, and its content in pharmaceutical composition of the present invention is generally 5-50% by the weight of said composition, is preferably 5-30%.
Also can comprise flavouring agent, coloring agent etc. in the pharmaceutical composition of the present invention.
The present invention also provides a kind of method for preparing the Acarbose medicine composition of described treatment diabetes, and it may further comprise the steps:
Dimethicone is added absorbent, and mix homogeneously adds acarbose, pharmaceutic adjuvant acceptable mix homogeneously, is processed into various solid dosage formss.
The pharmaceutical composition of treatment diabetes of the present invention can be made as oral various tablets, capsule, powder/granule, variously often releases, rapid release, controlled release or slow releasing preparation etc.
The pharmaceutical composition of treatment diabetes of the present invention is owing to adopted specific adjuvant and selected specific proportioning, between each component synergism is arranged, make medicine of the present invention both bring into play the drug effect of acarbose, eliminated the side effect of acarbose again, after taking, diabetics can not produce the many gas of intestinal, abdominal distention, eliminated the phenomenon of constipation simultaneously, product is stable curative effect, remarkable not only, and good moldability.
The specific embodiment
The following example is in order further to describe the present invention for example, rather than limits the present invention by any way.
Embodiment 1: a kind of acarbose composition tablet
Acarbose 50.0g
Dimethicone 50.0g
Basic magnesium carbonate 80.0g
Starch 200.0g
Carboxymethyl starch sodium 8.0g
Pulvis Talci 4.0g
Magnesium stearate 4.0g
Polyvinylpyrrolidone 2.0
Water 50ml
Its preparation method is as follows:
Dimethicone is added basic magnesium carbonate, mix homogeneously, add acarbose, starch, behind the mix homogeneously, add the mixed solution system soft material of polyvinylpyrrolidone and water, granulate, dry, granulate add carboxymethyl starch sodium, Pulvis Talci, magnesium stearate, mix homogeneously, tabletting promptly gets 1000.Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
Embodiment 2: a kind of acarbose composition tablet
Acarbose 120.0g
Dimethicone 80.0g
Micropowder silica gel 80.0g
Dextrin 150.0g
Sodium carboxymethyl cellulose 15.0g
Magnesium stearate 3.0g
Gelatin 4.0g
Water 50ml
Its preparation method is as follows:
Dimethicone is added micropowder silica gel, and mix homogeneously adds acarbose, dextrin, behind the mix homogeneously, the mixed liquor system soft material that adds gelatin and water is granulated, and dry, granulate add sodium carboxymethyl cellulose, magnesium stearate, mix homogeneously, tabletting promptly gets 1000.Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
Embodiment 3: a kind of acarbose composition capsule for the treatment of diabetes
Acarbose 70.0g
Dimethicone 30.0g
Micropowder silica gel 50.0g
Starch 180.0g
Carboxymethyl starch sodium 15.0g
Pulvis Talci 4.0g
Polyvinylpyrrolidone 3.0g
Water 50ml
Its preparation method is as follows:
Dimethicone is added micropowder silica gel, and mix homogeneously behind adding acarbose, starch, the carboxymethyl starch sodium mix homogeneously, adds the mixed liquor system soft material of polyvinylpyrrolidone and water, granulate drying, granulate, add Pulvis Talci, mixing is loaded capsule and is promptly got 1000.Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
Embodiment 4: a kind of acarbose composition capsule for the treatment of diabetes
Acarbose 70.0g
Dimethicone 30.0g
Micropowder silica gel 40.0g
Little smart cellulose 240.0g
Cross-linking sodium carboxymethyl cellulose 15.0g
Magnesium laurylsulfate 4.0g
Arabic gum 4.0g
Water 50ml
Its preparation method is as follows:
Dimethicone is added micropowder silica gel, and mix homogeneously adds acarbose, little smart cellulose, cross-linking sodium carboxymethyl cellulose, behind the mix homogeneously, add the mixed liquor system soft material of arabic gum and water, granulate drying, granulate adds magnesium laurylsulfate, and mixing is loaded capsule and promptly got 1000.
Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
Embodiment 5: a kind of acarbose composition granule
Acarbose 50.0g
Dimethicone 50.0g
Light magnesium oxide 100.0g
Starch 180.0g
Carboxymethylcellulose calcium 20.0g
Hydroxypropyl methylcellulose 3.0g
Water 50ml
Its preparation method is as follows:
Dimethicone is added light magnesium oxide, and mix homogeneously adds acarbose, starch, and carboxymethylcellulose calcium behind the mix homogeneously, adds the mixed liquor system soft material of hydroxypropyl methylcellulose and water, granulate, and drying, granulate, classification divides to be packaged into granule.Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
Embodiment 6: a kind of acarbose composition granule
Acarbose 75.0g
Dimethicone 50.0g
Micropowder silica gel 50.0g
Dextrin 200.0g
Pregelatinized Starch 25.0g
Polyvinylpyrrolidone 3.0g
Water 45ml
Its preparation method is as follows:
Dimethicone is added micropowder silica gel, and mix homogeneously adds acarbose, behind dextrin, the pregelatinized Starch mix homogeneously, adds the mixed liquor system soft material of polyvinylpyrrolidone and water, granulate, and drying, granulate, classification divides to be packaged into granule.Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
Embodiment 7: a kind of acarbose composition tablet (direct compression)
Acarbose 70.0g
Dimethicone 30.0g
Micropowder silica gel 50.0g
Pregelatinized Starch 245.0g
Pulvis Talci 5.0g
Its preparation method is as follows:
Dimethicone is added micropowder silica gel, and mix homogeneously adds acarbose, pregelatinized Starch, Pulvis Talci, behind the mix homogeneously, and direct compression.Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
Embodiment 8: a kind of acarbose composition capsule
Acarbose 70.0g
Dimethicone 30.0g
Micropowder silica gel 50.0g
Pregelatinized Starch 248.0g
Its preparation method is as follows:
Dimethicone is added micropowder silica gel, and mix homogeneously adds acarbose, pregelatinized Starch, behind the mix homogeneously, directly adds encapsulated.Generally according to acarbose cubage 50～200mg/ time, 3 times/day, taking medicine before meal is used.
The pharmacodynamics example
Below effect by pharmacodynamic experiment explanation acarbose composite preparation of the present invention
Acarbose composite preparation of the present invention is to the research of mice flatulence phenomenon
One, experimental technique:
70 of healthy Kunming mouses, male and female half and half, body weight 18～22g.Be divided into normal control group, the high, medium and low dosage of acarbose medicine and the high, medium and low dosage group of the embodiment of the invention 1 Acarbose medicine composition preparation at random, 10 every group.The male and female sub-cage rearing.
The high, medium and low dosage group of different preparations is irritated the medicine that stomach gives 50mg/kg, 100mg/kg, 200mg/kg (amount that is equivalent to acarbose) respectively, free diet drinking-water after the administration.
The mice volumetrical measuring method of intestinal that expands: mouse stomach after 2 hours the cervical region dislocation put to death, dissect and open the abdominal cavity and separate mesentery.The clip upper end is the part to the ileocecum end from the pylorus lower end, lives with gas leakage prevention with linear system earlier before cut off at two ends, surveys the intestinal volume that expands with the draining measurement method.
Two, result
It is as shown in table 1 that the draining measurement method records each bloated intestinal volume of organizing.
The different preparations of table 1. acarbose are to the influence of intestinal tympanites volume (n=10, x ± SD)
| Group | Dosage (mg/kg) | Body weight (g, x ± SD) | The flatulence volume (ml, x ± SD) |
| The normal control group acarbose embodiment of the invention 1 acarbose compositions | -- 50 100 200 50 100 200 | 20.8±1.2 21.3±1.6 20.9±1.1 20.3±1.7 19.6±1.5 21.3±2.1 21.0±1.8 | 2.55±0.48 2.94±0.43 * 3.24±0.67 * 3.68±0.36 * 2.58±0.53 a 2.61±0.23 b 2.78±0.55 *c |
Compare with the normal control group,
*P＜0.05; With comparing between the dosage group
aP＜0.05,
bP＜0.05,
cP＜0.05.
Three, conclusion
Compare with the normal control group,
*P＜0.05 illustrates that the basic, normal, high dosage of acarbose all can significantly cause flatulence, and acarbose composite preparation high dose group of the present invention also has the side effect that causes flatulence simultaneously; But acarbose group and acarbose composite preparation of the present invention show with comparative result between the dosage group, acarbose composite preparation of the present invention has significant improvement effect to flatulence, point out acarbose composite preparation of the present invention aspect side effect, to be significantly less than the acarbose group, be more suitable for clinical application.
Acarbose composite preparation of the present invention is to the influence of dryness accumulated in the stomach and intestine type mice with constipation bowel movement function
One, experimental technique:
Get healthy Kunming mouse, press literature method feed every day rice, prohibit water (comprising all aqueous vegetables etc.) 3 days, yellowish or reddish urine appears in mice, and constipation with dry stool is the garden pearl, or beading, loses weight, and is judged as the constipation of mice dryness accumulated in the stomach and intestine type.
Get 70 of above-mentioned dryness accumulated in the stomach and intestine type mice with constipation, male and female half and half, body weight 18～22g.Be divided into model control group, the high, medium and low dosage of acarbose and the high, medium and low dosage group of the embodiment of the invention 1 acarbose composite preparation at random, 10 every group.The male and female sub-cage rearing.
The high, medium and low dosage group of different preparations is irritated the medicine that stomach gives 50mg/kg, 100mg/kg, 200mg/kg (amount that is equivalent to acarbose) respectively, and matched group gives the normal saline of equal volume.Pick up counting after the administration, write down animal defecation grain number and weight in 4 and 8 hours.
Two, result
The different preparations of table 1. acarbose are to the influence of dryness accumulated in the stomach and intestine type mice with constipation bowel movement function (n=10, x ± SD)
| Group | Dosage (mg/kg) | Defecation grain number (x ± SD) | Defecation weight (mg, x ± SD) | ||
| 4hours | 8hours | 4hours | 8hours | ||
| The model control group acarbose embodiment of the invention 1 acarbose compositions | Physiological saline 50 100 200 50 100 200 | 0.70±1.05 0.60±0.94 0.78±0.82 0.90±1.22 1.03±1.10 0.80±0.84 1.60±2.38 | 10.8±7.2 11.3±8.2 10.9±7.1 13.4±5.7 19.6±5.5 * 21.3±6.1 * 26.0±8.2 * | 10.6±16.9 9.2±15.3 11.9±14.7 21.0±26.8 27.2±29.3 13.7±15.2 32.7±48.2 | 139±112 145±110 140±87 168±69 288±73 * 331±123 * 378±115 * |
Compare with model control group,
*P＜0.05.
Three, conclusion
Compare with model control group,
*P＜0.05 illustrates that acarbose composite preparation of the present invention significantly improves the bowel movement function of dryness accumulated in the stomach and intestine type mice with constipation.Therefore point out Acarbose medicine composition preparation of the present invention also to have functions of loosening bowel relieving constipation simultaneously, be worth further Application and Development at its indication of treatment.
Claims (10)
1. Acarbose medicine composition for the treatment of diabetes, by the weight of this pharmaceutical composition, it comprises
Acarbose 1-50%,
Dimethicone 1-50%,
Absorbent 5-80%,
Pharmaceutic adjuvant acceptable 10-90%,
Wherein the weight ratio of acarbose and dimethicone is 1: 10-20: 1.
2. according to the Acarbose medicine composition of claim 1, by the weight of this pharmaceutical composition, it comprises:
Acarbose 5-50%,
Dimethicone 5-50%,
Absorbent 5-70%,
Pharmaceutic adjuvant acceptable 20-80%,
Wherein the weight ratio of acarbose and dimethicone is 1: 5-15: 1.
3. according to the Acarbose medicine composition of claim 2, by the weight of this pharmaceutical composition, it comprises:
Acarbose 5-30%,
Dimethicone 5-20%,
Absorbent 10-50%,
Pharmaceutic adjuvant acceptable 20-60%,
Wherein the weight ratio of acarbose and dimethicone is 1: 4-10: 1.
4. according to the Acarbose medicine composition of claim 3, described absorbent is one or more any mixture in starch, magnesium oxide, light magnesium oxide, silica gel, micropowder silica gel, magnesium carbonate, the basic magnesium carbonate, preferred micropowder silica gel.
5. according to the Acarbose medicine composition of claim 4, described pharmaceutic adjuvant acceptable comprises one or more any mixture in diluent, disintegrating agent, binding agent, lubricant, fluidizer and the solvent.
6. according to the Acarbose medicine composition of claim 5, described disintegrating agent comprises dried starch, pregelatinized Starch, little smart cellulose, alginic acid and salt thereof, carboxymethyl starch sodium, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, methylcellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, the any mixture of one or more in the carboxymethylcellulose calcium, its content is counted 0.5-20% by the weight of said composition, is preferably 1-8%.
7. according to the Acarbose medicine composition of claim 6, described binding agent comprises one or more any mixture in polyvinylpyrrolidone, starch, pregelatinized Starch, gelatin, arabic gum, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, the hydroxypropyl methyl fiber, its content is counted 0.1-60% by the weight of said composition, preferred 0.2-20%.
8. according to the Acarbose medicine composition of claim 7, described lubricant comprises magnesium stearate, calcium stearate, Glyceryl Behenate, the any mixture of one or more in glyceryl monostearate, stearic acid, hydrogenated vegetable oil, month pure magnesium sulfate of extension, polyethylene glycols, the Pulvis Talci, its content is counted 0.1-5% by the weight of said composition, is preferably 0.5-2%; Described fluidizer comprises Pulvis Talci, Powderd cellulose, magnesium silicate, and the mixture of one or more in magnesium trisilicate, the magnesium stearate, its content is counted 0.1-5% by the weight of said composition, is preferably 0.5-2%.
9. according to the Acarbose medicine composition of claim 1-8, it is made into tablet, capsule, powder/granule, variously often releases, rapid release, controlled release or slow releasing preparation dosage form.
10. preparation is according to the method for the Acarbose medicine composition of claim 1-9, and it may further comprise the steps:
Dimethicone is added absorbent, and mix homogeneously adds acarbose, pharmaceutic adjuvant acceptable mix homogeneously, is processed into various solid dosage formss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510135551XA CN100389774C (en) | 2005-12-30 | 2005-12-30 | Medicinal composition for treating diabetes and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510135551XA CN100389774C (en) | 2005-12-30 | 2005-12-30 | Medicinal composition for treating diabetes and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1823795A true CN1823795A (en) | 2006-08-30 |
| CN100389774C CN100389774C (en) | 2008-05-28 |
Family
ID=36934736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510135551XA Expired - Fee Related CN100389774C (en) | 2005-12-30 | 2005-12-30 | Medicinal composition for treating diabetes and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100389774C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546795A (en) * | 2015-02-06 | 2015-04-29 | 杭州朱养心药业有限公司 | Acarbose capsule and preparation method thereof |
| WO2016192098A1 (en) * | 2015-06-05 | 2016-12-08 | 台中荣民总医院 | Pharmaceutical composition containing acarbose and use thereof in regulating immunization |
| CN109276704A (en) * | 2017-11-07 | 2019-01-29 | 江苏省中医药研究院 | Purposes of the melittin in the drug or health care product of preparation treatment and/or prevention diabetes |
| CN110812344A (en) * | 2019-12-17 | 2020-02-21 | 卓和药业集团有限公司 | Pharmaceutical composition for treating diabetes complicated with angina pectoris and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA992000B (en) * | 1998-03-12 | 1999-09-13 | Procter & Gamble | Disposable absorbent article having a skin care composition containing an enzyme inhibitor. |
| AU2003225102A1 (en) * | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
-
2005
- 2005-12-30 CN CNB200510135551XA patent/CN100389774C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546795A (en) * | 2015-02-06 | 2015-04-29 | 杭州朱养心药业有限公司 | Acarbose capsule and preparation method thereof |
| CN104546795B (en) * | 2015-02-06 | 2018-02-02 | 杭州朱养心药业有限公司 | Acarbose capsules agent and preparation method |
| WO2016192098A1 (en) * | 2015-06-05 | 2016-12-08 | 台中荣民总医院 | Pharmaceutical composition containing acarbose and use thereof in regulating immunization |
| CN107106583A (en) * | 2015-06-05 | 2017-08-29 | 台中荣民总医院 | Medical composition comprising acarbose and its purposes for immunological regulation |
| CN107106583B (en) * | 2015-06-05 | 2021-04-13 | 台中荣民总医院 | Pharmaceutical compositions comprising acarbose and their use for immunomodulation |
| CN109276704A (en) * | 2017-11-07 | 2019-01-29 | 江苏省中医药研究院 | Purposes of the melittin in the drug or health care product of preparation treatment and/or prevention diabetes |
| CN110812344A (en) * | 2019-12-17 | 2020-02-21 | 卓和药业集团有限公司 | Pharmaceutical composition for treating diabetes complicated with angina pectoris and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100389774C (en) | 2008-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1278179A (en) | Use of alpha-glucosidase ihibitor for treating high-risk impaired clucose tolerance | |
| CN87105828A (en) | The quick-acting compositionss of sulindac or sodium sulindac and alkali | |
| CN111494357A (en) | Treatment of metabolic disorders in felines | |
| CN1729005A (en) | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations | |
| CN1823795A (en) | Medicinal composition for treating diabetes and its preparation method | |
| CN1857264A (en) | Medicine composition with pioglitazone hydrochloride and glimepiride as active components and its preparing method and use | |
| CN1498659A (en) | Nutritious supplementing agent contg. a-glucosidase inhibitor and a-amylase inhibitor | |
| CN1901927A (en) | Alpha-glucosidase activity inhibitor | |
| CN1651088A (en) | Effervescent preparation using alditol as functional ingredient | |
| CN1785188A (en) | Compounding metformin glipidide prepn. for treating diabetes type II, and its prepn. method | |
| CN1287860C (en) | Combination of medication containing reductase inhibitor HMG CoA and Melatonin | |
| CN1895250A (en) | Gliquilone slow-releasing preparation | |
| CN1539429A (en) | Deoxyadenosine in aplication of preparing bypolipidemic | |
| CN1726916A (en) | Oral disintegration tablet for dropping blood sugar and preparation method | |
| CN1739502A (en) | Application of benzydalysine in preparing medicine for treating diabetic peripheral neuropathy | |
| CN1295231C (en) | Bromo-dihydroartemisine | |
| CN1552327A (en) | Oral ofloxacin control-sustained releasing medicinal composition | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN1304021C (en) | Medicinal composition and its preparing method | |
| CN1209109C (en) | Slow-releasing acipimox tablet | |
| CN100335056C (en) | Pharmaceutical composition and its application in preparation of medicine for treating type II diabetes | |
| CN1273175C (en) | Preparation method of ginseng fruit extractive and its medicinal usage for treating diabetes | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN1471912A (en) | Oral film agent of vanadium biguanide complex for diabetes and its use | |
| CN1857368A (en) | Medicine composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080528 Termination date: 20171230 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |